Redox Modulation of Prostate Cancer
Redox Modulation of Prostate Cancer
批准号:
7257520
负责人:
WILLIAM H ST CLAIR
金额:
$27.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-01 至 2012-05-31
关键词:
AEOL10113AndrogensAnimalsAntibodiesAntioxidantsAreaBasic ScienceBindingBinding SitesBiological PreservationCancer EtiologyCell DeathCell LineCell ProliferationCell SurvivalCellsCessation of lifeCharacteristicsClinicalClinical TreatmentClone CellsCodeComplementComplicationCoupledCritiquesDailyDataDevelopmentDiarrheaDisadvantagedDominant-Negative MutationDoseElectron MicroscopyEnsureEnzymesEpitopesEvaluationFamilyFecal IncontinenceFigs - dietaryFree RadicalsFundingGene ExpressionGene TargetingGenerationsGenesGenetic Enhancer ElementGenetic TranscriptionGleason Grade for Prostate CancerGoalsGrantGrowthHemorrhageHeterogeneityHormonesHumanImage AnalysisImmune responseImmunityImmunologyImplantIn VitroInjection of therapeutic agentInjuryInterruptionInterventionIntestinesInvestigationIonizing radiationKineticsLNCaPLeadLightLinkLocalizedLocationMalignant NeoplasmsMalignant neoplasm of prostateManganese Superoxide DismutaseManuscriptsMeasuresMediatingMethodologyMethodsMicroscopeModelingMonitorMusMutateNF-kappa BNatureNormal CellNormal tissue morphologyNuclearNuclear TranslocationNude MiceNumbersOutcomeOxidation-ReductionOxidative StressPC3 cell linePathologistPathway interactionsPatientsPatternPelvisPeptidesPersonal SatisfactionPhysiciansPlayPolymerase Chain ReactionPopulationPostdoctoral FellowProcessProctitisProductionPromoter RegionsProstateProtein OverexpressionProteinsPublicationsPublishingRadiationRadiation ToleranceRadiation therapyRadiobiologyRangeRapid Access to Intervention DevelopmentRateReactive Oxygen SpeciesRectumRegulationRegulator GenesRelative (related person)ReportingResearchResearch PersonnelResistanceResourcesReverse Transcriptase Polymerase Chain ReactionRoleSN50 peptideSalineSamplingScheduleScientistSerumSignal TransductionSkin NeoplasmsSmall Interfering RNAStaining methodStainsStandards of Weights and MeasuresStreamSubcellular FractionsSubcutaneous InjectionsTNFRSF5 geneTP53 geneTestingTetanus Helper PeptideTherapeuticTherapeutic AgentsTherapeutic InterventionTimeTissuesTopical applicationToxicologyTranslatingUniversitiesVariantWeekWisconsinandrogen independent prostate canceranimal tissueanticancer researchbalsalazidebasecancer cellcancer therapyconceptdaydesigndirect applicationimmunogenicimplantationimprovedin vitro Modelin vivoin vivo Modelinhibitor/antagonistinsightinterestintracellular protein transportirradiationknock-downmalemembermenmimeticsmutantneoplastic cellnovel strategiesp65preventprogramspromoterprotein aminoacid sequenceprotein localization locationradiation effectradiation resistancerectalreproductiveresearch studyresponsestable cell linesurvivinsynthetic peptidetranscription factortumorvector
中文摘要
描述(由申请人提供):核因子κ β(NF-κ B)是一种氧化还原敏感性转录因子,被公认为编码促凋亡和促存活蛋白的基因的调节因子。已经表明,非依赖性前列腺癌具有高组成性水平的NF-kB,并且癌症治疗剂对NF-kB的活化可以减弱这些药剂的活性以引起癌细胞死亡。该项目的目标是深入了解NF-kB介导的导致内在辐射抗性的机制,并确定可用于改善前列腺癌治疗的新方法。我们的初步数据表明,雄激素非依赖性前列腺癌具有高水平的选定成员的NF-κ B家族及其促生存NF-κ B靶基因产物,包括主要的抗氧化酶,锰超氧化物歧化酶,和抗凋亡蛋白,Bcl-XL。我们还发现,辐射诱导激活NF-κ B的两波模式。我们假设,具有高水平的组成性NF-κ B的肿瘤细胞将对NF-κ B介导的细胞保护途径的抑制敏感,并且该途径的调节可以改善侵袭性前列腺癌的放射反应。亲本PC-3及其NF-kB突变体衍生的细胞系将用作雄激素非依赖性前列腺癌细胞的模型。亲本LNCaP及其相应的衍生物将用作雄激素依赖性前列腺癌细胞的模型。将在体外和体内研究充分表征的PC-3衍生的以及LNCaP衍生的前列腺癌细胞系。将5周龄雄性无胸腺裸鼠用作人前列腺癌细胞的宿主,通过原位植入前列腺。具体目标1旨在鉴定在侵袭性前列腺癌细胞的高内在放射抗性中起重要作用的NF-κ B家族的特定成员。具体目标2旨在测试选择性调节NF-κ B或基于氧化还原的干预可用于增强辐射敏感性的概念。具体目标3旨在在实验治疗环境中验证具体目标2的结果。这项研究的完成将增强我们对NF-kB家族成员参与细胞存活的机制的理解。这一信息可以作为选择性方法的发展的基本原理,最终可能转化为显着的临床效益。
英文摘要
DESCRIPTION (provided by applicant): The nuclear factor kappa beta (NF-kB), a redox-sensitive transcription factor, is well established as a regulator of genes coding for both proapoptosis and prosurvival proteins. It has been shown that hormone-independent prostate cancer has a high constitutive level of NF-kB and activation of NF-kB by cancer therapeutic agents can blunt the activity of these agents to cause cancer cell death. The goal of this project is to gain insight into an NF-kB mediated mechanism leading to intrinsic radiation resistance and to identify novel approaches that can be used to improve the treatment of prostate cancer. Our initial data demonstrate that androgen-independent prostate cancer has high levels of selected members of the NF-kB family and its prosurvival NF-kB target gene products including the primary antioxidant enzyme, manganese superoxide dismutase, and the antiapoptotic protein, BclXL. We also found that radiation induced activation of NF-kB in a two-wave pattern. We hypothesize that tumor cells with high levels of constitutive NF-kB will be sensitive to inhibition of the NF-kB mediated cytoprotective pathway and modulation of this pathway can improve the radiation response of aggressive prostate cancer. Parental PC-3 and its NF-kB mutant derived cell lines will be used as models for androgen-independent prostate cancer cells. Parental LNCaP and its corresponding derivatives will be used as models for androgen-dependent prostate cancer cells. Well characterized PC-3 derived as well as LNCaP derived prostate cancer cell lines will be studied in vitro and in vivo. Five-weeks-old male athymic nude mice will be used as hosts of human prostate cancer cells by orthotopic implantation in the prostate glands. Specific aim 1 is designed to identify specific members of the NF-kB family that play an important role in high intrinsic radioresistance of aggressive prostate cancer cells. Specific aim 2 is designed to test the concept that selective modulation of NF-kB or redox-based intervention can be used to enhance radiation sensitivity. Specific aim 3 is designed to validate the results from Specific aim 2 in an experimental therapeutic setting. Accomplishment of this study will enhance our understanding of the mechanisms by which members of the NF-kB family participate in cell survival. This information can serve as a rationale for the development of selective approaches that might eventually translate into significant clinical benefit.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Redox Modulation of Prostate Cancer
-
批准号:7478583
-
项目类别:
-
资助金额:$25.05万
-
财政年份:2007
-
负责人:WILLIAM H ST CLAIR
-
依托单位:
Redox Modulation of Prostate Cancer
-
批准号:7843722
-
项目类别:
-
资助金额:$25.05万
-
财政年份:2007
-
负责人:WILLIAM H ST CLAIR
-
依托单位:
Redox Modulation of Prostate Cancer
-
批准号:8079690
-
项目类别:
-
资助金额:$24.3万
-
财政年份:2007
-
负责人:WILLIAM H ST CLAIR
-
依托单位:
Redox Modulation of Prostate Cancer
-
批准号:7649277
-
项目类别:
-
资助金额:$25.05万
-
财政年份:2007
-
负责人:WILLIAM H ST CLAIR
-
依托单位:
BOWMAN-BIRK PROTEASE INHIBITOR EFFECTS ON ONCOGENE EXPRESSION; COLON
-
批准号:3889912
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WILLIAM H ST CLAIR
-
依托单位:
INFLUENCE OF BOWMAN-BIRK PROTEINASE INHIBITOR ON ONCOGENE EXPRESSION
-
批准号:3930193
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WILLIAM H ST CLAIR
-
依托单位:
CELLULAR TRANSFORMED BY TOBACCO LEAF PROTEASE INHIBIT: CHYMOTRYPSIN INHIBITOR I
-
批准号:3868523
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WILLIAM H ST CLAIR
-
依托单位:
PROTEASE INHIBITOR ON ONCOGENE EXPRESSION, CELL PROLIFERATION & TUMORIGENESIS
-
批准号:3909060
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WILLIAM H ST CLAIR
-
依托单位:
海外基金